| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1993;55:1033-1041
© 1993 The Society of Thoracic Surgeons
Department of Cardiac Surgery, Oxford Heart Centre, John Radcliffe Hospital, Oxford, England
* Address reprint requests to Dr Westaby, Oxford Heart Centre, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, England.
Aprotinin is a nonspecific serine protease inhibitor extracted from bovine lung. It was first used during cardiopulmonary bypass to inhibit plasmin-induced complement activation. By chance significant reductions of blood loss and blood requirements were noted in treated patients. Subsequent investigation showed improved hemostasis to result from protection of platelet adhesive receptors (Gp Ib) at the onset of cardiopulmonary bypass. Without aprotinin the contact system of plasma is massively activated on first passage through the cardiopulmonary bypass circuit. Activation of the intrinsic coagulation pathway causes thrombin formation, which impairs platelet adhesive function. Aprotinin blocks contact activation of the kallekrein system during cardiopulmonary bypass and in synergy with heparin prevents thrombin formation through inhibition of the intrinsic clotting cascade. It is likely that neither thrombin nor platelets become involved in the blood-foreign surface contact activation process in aprotinin-treated patients. The fact that the hemostatic process is affected from the very beginning of cardiopulmonary bypass is substantiated by the fact that low-dose aprotinin therapy (2 x 106 KIU aprotinin added to the pump prime) leads to the same preservative effect on Gp Ib receptors and blood loss as continuous high-dose infusion (6 x 106 KIU) throughout the whole surgical procedure. In the presence of heparin aprotinin prolongs the activated clotting time and the in vitro activated partial thromboplastin time. This has important implications for heparin dosage. An inhibitory effect on the endothelial cell anticoagulant function may also have consequences during hypothermic low flow and circulatory arrest states. Early clinical trials in patients undergoing first operations or reoperations for coronary artery disease confirmed the hemostatic and blood-sparing properties with no apparent adverse effects. Consequently some workers recommend routine use of this agent in every patient undergoing cardiopulmonary bypass. However, evidence is now accumulating to suggest that aprotinin increases the risk of perioperative myocardial infarction during coronary operations and has other potentially fatal adverse effects in certain other groups of patients. In view of these findings a logical approach to the use of aprotinin must be considered.
This article has been cited by other articles:
|
|
 |
|
  Y. Iwata, T. Okamura, N. Ishibashi, D. Zurakowski, H. G.W. Lidov, and R. A. Jonas Optimal dose of aprotinin for neuroprotection and renal function in a piglet survival model. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1521 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Westaby Aprotinin: Twenty-five years of claim and counterclaim J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 487 - 491. [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwata, O. Nicole, T. Okamura, D. Zurakowski, and R. A. Jonas Aprotinin confers neuroprotection by reducing excitotoxic cell death J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 573 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Durgut, K. Hosgor, N. Gormus, U. Ozergin, and H. Solak The cerebroprotective effects of pentoxifylline and aprotinin during cardiopulmonary bypass in dogs Perfusion, March 1, 2004; 19(2): 101 - 106. [Abstract] [PDF]
|
|
|
|
|
|
D. Schmartz, Y. Tabardel, J.-C. Preiser, L. Barvais, A. d'Hollander, J. Duchateau, and J.-L. Vincent Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients? J. Thorac. Cardiovasc. Surg., January 1, 2003; 125(1): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Baufreton, J. L. de Brux, P. Binuani, J.-J. Corbeau, J. B. Subayi, J. C. Daniel, and P. Treanor A combined approach for improving cardiopulmonary bypass in coronary artery surgery: a pilot study Perfusion, December 1, 2002; 17(6): 407 - 413. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Ulker, P. P McKeown, and U. Bayraktutan Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells Cardiovasc Res, September 1, 2002; 55(4): 830 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M D Linden, M Schneider, and W N Erber Factor VLEIDEN and cardiopulmonary bypass: investigation of haemostatic parameters and the effect of aprotinin using an ex vivo model Perfusion, December 1, 2001; 16(6): 476 - 484. [Abstract] [PDF]
|
|
|
|
|
|
K. N. Sturk-Maquelin, R. Nieuwland, and A. Sturk Reply J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 405 - 406. [Full Text] [PDF]
|
|
|
|
|
|
S. Ulker, M. G. Cinar, U. Bayraktutan, and A. Evinc Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells Cardiovasc Res, June 1, 2001; 50(3): 589 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Mojcik and J. H. Levy Aprotinin and the systemic inflammatory response after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2001; 71(2): 745 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-O. Defraigne, J. Pincemail, G. Dekoster, R. Larbuisson, M. Dujardin, F. Blaffart, J.-L. David, and R. Limet SMA circuits reduce platelet consumption and platelet factor release during cardiac surgery Ann. Thorac. Surg., December 1, 2000; 70(6): 2075 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rahman, B. Ustunda, O. Burma, I. H. Ozercan, A. Cekirdekci, and M. K. Bayar Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass? Eur J Cardiothorac Surg, November 1, 2000; 18(5): 583 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K Biswas, L. Lewis, and J. F Sommerauer Aprotinin in the management of life-threatening bleeding during extracorporeal life support Perfusion, May 1, 2000; 15(3): 211 - 216. [Abstract] [PDF]
|
|
|
|
|
|
B. I. Wong, R. F. McLean, S. E. Fremes, K. A. Deemar, E. M. Harrington, G. T. Christakis, and B. S. Goldman Aprotinin and tranexamic acid for high transfusion risk cardiac surgery Ann. Thorac. Surg., March 1, 2000; 69(3): 808 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Westaby Anti-fibrinolytic therapy in thoracic aortic surgery Ann. Thorac. Surg., June 1, 1999; 67(6): 1983 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hyde, J. A Chinn, and T. R Graham Platelets and cardiopulmonary bypass Perfusion, December 1, 1998; 13(6): 389 - 407. [PDF]
|
|
|
|
|
|
R. G.H. Speekenbrink, R. M. Bertina, F. Espana, C. R.H. Wildevuur, and L. Eijsman Activation of the protein C system during cardiopulmonary bypass with and without aprotinin Ann. Thorac. Surg., December 1, 1998; 66(6): 1998 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Carrel, M. Schwanda, P. R. Vogt, and M. I. Turina Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only Ann. Thorac. Surg., July 1, 1998; 66(1): 153 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Roberts, G. P. Nishanian, J. N. Carey, S. H. Darbinian, J. D. Kim, Y. Sakamaki, J. Y. Chang, V. A. Starnes, and M. L. Barr Addition of aprotinin to organ preservation solutions decreases lung reperfusion injury Ann. Thorac. Surg., July 1, 1998; 66(1): 225 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cohen, J. Ivanov, R. D. Weisel, V. Rao, M. K. Mohabeer, and D. A. G. Mickle Aprotinin and Dipyridamole for the Safe Reduction of Postoperative Blood Loss Ann. Thorac. Surg., March 1, 1998; 65(3): 674 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Westaby and T. Katsumata Proximal aortic perfusion for complex arch and descending aortic disease J. Thorac. Cardiovasc. Surg., January 1, 1998; 115(1): 162 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Westaby Aprotinin Fifteen Years Later Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 366 - 375. [Abstract] [PDF]
|
|
|
|
|
|
N. Hayashida, T. Isomura, T. Sato, H. Maruyama, K. Kosuga, and S. Aoyagi EFFECTS OF MINIMAL-DOSE APROTININ ON CORONARY ARTERY BYPASS GRAFTING J. Thorac. Cardiovasc. Surg., August 1, 1997; 114(2): 261 - 269. [Abstract] [Full Text]
|
|
|
|
 |
|
 O. Shigeta, H. Kojima, T. Jikuya, Y. Terada, N. Atsumi, Y. Sakakibara, T. Nagasawa, and T. Mitsui Aprotinin Inhibits Plasmin-Induced Platelet Activation During Cardiopulmonary Bypass Circulation, July 15, 1997; 96(2): 569 - 574. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Coady, J. A. Rizzo, G. L. Hammond, D. Mandapati, U. Darr, G. S. Kopf, and J. A. Elefteriades WHAT IS THE APPROPRIATE SIZE CRITERION FOR RESECTION OF THORACIC AORTIC ANEURYSMS? J. Thorac. Cardiovasc. Surg., March 1, 1997; 113(3): 476 - 491. [Abstract] [Full Text]
|
|
|
|
|
|
C. Baufreton, P. G. M. Jansen, P. Le Besnerais, H. Velthuis, C. M. Thijs, C. R. H. Wildevuur, and D. Y. Loisance Heparin Coating With Aprotinin Reduces Blood Activation During Coronary Artery Operations Ann. Thorac. Surg., January 1, 1997; 63(1): 50 - 56. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ashraf, Y. Tian, D. Cowan, U. Nair, R. Chatrath, N. R. Saunders, K. G. Watterson, and P. G. Martin "Low-Dose" Aprotinin Modifies Hemostasis but Not Proinflammatory Cytokine Release Ann. Thorac. Surg., January 1, 1997; 63(1): 68 - 73. [Abstract] [Full Text]
|
|
|
|
|
|
C. Baufreton, P. Le Besnerais, P. Jansen, J. P. Mazzucotelli, C. R. Wildevuur, and D. Y Loisance Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass Perfusion, November 1, 1996; 11(6): 437 - 443. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Tweddell, S. Berger, P. C. Frommelt, A. N. Pelech, D. A. Lewis, R. T. Fedderly, M. A. Frommelt, T. S. McManus, Ccp, K. A. Mussatto, et al. Aprotinin Improves Outcome of Single-Ventricle Palliation Ann. Thorac. Surg., November 1, 1996; 62(5): 1329 - 1335. [Abstract] [Full Text]
|
|
|
|
|
|
T. J. Vander Salm, S. Kaur, R. A. Lancey, O. N. Okike, A. T. Pezzella, R. F. Stahl, L. Leone, J.-M. Li, C. R. Valeri, and A. D. Michelson REDUCTION OF BLEEDING AFTER HEART OPERATIONS THROUGH THE PROPHYLACTIC USE OF EPSILON-AMINOCAPROIC ACID J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1098 - 1107. [Abstract] [Full Text]
|
|
|
|
|
|
T. W. Prendergast, S. Furukawa, A. J. Beyer III, H. J. Eisen, J. B. McClurken, and V. Jeevanandam Defining the Role of Aprotinin in Heart Transplantation Ann. Thorac. Surg., September 1, 1996; 62(3): 670 - 674. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Kichuk, N. Seyedi, X. Zhang, C. C. Marboe, R. E. Michler, L. J. Addonizio, G. Kaley, A. Nasjletti, and T. H. Hintze Regulation of Nitric Oxide Production in Human Coronary Microvessels and the Contribution of Local Kinin Formation Circulation, July 1, 1996; 94(1): 44 - 51. [Abstract] [Full Text]
|
|
|
|
|
|
M.-C. Seghaye, J. Duchateau, R. G. Grabitz, K. Jablonka, T. Wenzl, C. Marcus, B. J. Messmer, and G. von Bernuth Influence of Low-Dose Aprotinin on the Inflammatory Reaction Due to Cardiopulmonary Bypass in Children Ann. Thorac. Surg., April 1, 1996; 61(4): 1205 - 1211. [Abstract] [Full Text]
|
|
|
|
|
|
L. Martinelli, M. Maurelli, M. Vigano', and M. C. Oz Aprotinin in Staged Heart Transplantation: Anaphylactic Potential of Repeated Exposure Ann. Thorac. Surg., April 1, 1996; 61(4): 1288 - 1289. [Full Text]
|
|
|
|
 |
|
 M. S. Dennis, A. Herzka, and R. A. Lazarus Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display J. Biol. Chem., October 27, 1995; 270(43): 25411 - 25417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy, R. Pifarre, H. V. Schaff, J. C. Horrow, R. Albus, B. Spiess, T. K. Rosengart, J. Murray, R. E. Clark, P. Smith, et al. A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting Circulation, October 15, 1995; 92(8): 2236 - 2244. [Abstract] [Full Text]
|
|
|
|
|
|
P. R. Feindt, S. Walcher, I. Volkmer, H. E. Keller, U. Straub, H. Huwer, U. T. Seyfert, T. Petzold, and E. Gams Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting Ann. Thorac. Surg., October 1, 1995; 60(4): 1076 - 1080. [Abstract] [PDF]
|
|
|
|
|
|
E. A. Bukhari, I. B. Krukenkamp, P. G. Burns, G. R. Gaudette, J. J. Schulman, M. R. Al-Fagih, and S. Levitsky Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning? Ann. Thorac. Surg., August 1, 1995; 60(2): 307 - 310. [Abstract] [PDF]
|
|
|
|
|
|
A. Shinfeld, D. Zippel, J. Lavee, A. Lusky, E. Shinar, N. Savion, and R. Mohr Aprotinin improves hemostasis after cardiopulmonary bypass better than single-donor platelet concentrate Ann. Thorac. Surg., April 1, 1995; 59(4): 872 - 876. [Abstract] [PDF]
|
|
|
|
|
|
J. H. Lemmer Jr, W. Stanford, S. L. Bonney, E. V. Chomka, R. B. Karp, G. W. Laub, J. A. Rumberger, and H. V. Schaff Aprotinin for coronary artery bypass grafting: Effect on postoperative renal function Ann. Thorac. Surg., January 1, 1995; 59(1): 132 - 136. [Abstract] [PDF]
|
|
|
|
|
|
N. Tabuchi, T. L. Njo, I. Tigchelaar, R. J. Huyzen, P. W. Boonstra, and W. van Oeveren Monitoring of anticoagulation in aprotinin-treated patients during heart operation Ann. Thorac. Surg., September 1, 1994; 58(3): 774 - 777. [Abstract] [PDF]
|
|
|
|
|
|
D. J. O'Regan, N. Giannopoulos, N. Mediratta, S. W. H. Kendall, A. Forni, R. Pillai, and S. Westaby Topical aprotinin in cardiac operations Ann. Thorac. Surg., September 1, 1994; 58(3): 778 - 781. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Coselli, S. Buket, and G. D. van Cleve Successful reoperation for ascending aorta and arch aneurysm in a Jehovah's witness Ann. Thorac. Surg., September 1, 1994; 58(3): 871 - 873. [Abstract] [PDF]
|
|
|
|
|
|
C. R. Smith, L. B. Mongero, C. M. DeRosa, R. E. Michler, and M. C. Oz Safety of aprotinin in profound hypothermia and circulatory arrest Ann. Thorac. Surg., August 1, 1994; 58(2): 606 - 607. [PDF]
|
|
|
|
|
|
W. M. DeCampli, D. Goodwin, J. C. Kosek, C. E. Handen, R. S. Mitchell, D. C. Miller, and A. DeAnda Jr Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs Ann. Thorac. Surg., March 1, 1994; 57(3): 778 - 780. [Abstract] [PDF]
|
|
|
|
|
|
T. M. Sundt, N. T. Kouchoukos, J. E. Saffitz, S. F. Murphy, T. H. Wareing, and D. J. Stahl Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest Ann. Thorac. Surg., June 1, 1993; 55(6): 1418 - 1424. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
